Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.
Turner RS, Hebron ML, Lawler A, Mundel EE, Yusuf N, Starr JN, Anjum M, Pagan F, Torres-Yaghi Y, Shi W, Mulki S, Ferrante D, Matar S, Liu X, Esposito G, Berkowitz F, Jiang X, Ahn J, Moussa C. Turner RS, et al. Among authors: liu x. Ann Neurol. 2020 Jul;88(1):183-194. doi: 10.1002/ana.25775. Epub 2020 May 28. Ann Neurol. 2020. PMID: 32468646 Free PMC article.
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Arellano J, Howard HH, Peyton M, Matar S, Liu X, Fowler AJ, Schwartz SL, Ahn J, Moussa C. Pagan FL, et al. Among authors: liu x. Pharmacol Res Perspect. 2019 Mar 12;7(2):e00470. doi: 10.1002/prp2.470. eCollection 2019 Apr. Pharmacol Res Perspect. 2019. PMID: 30906562 Free PMC article. Clinical Trial.
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. Among authors: liu x. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.
Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.
Fowler AJ, Hebron M, Balaraman K, Shi W, Missner AA, Greenzaid JD, Chiu TL, Ullman C, Weatherdon E, Duka V, Torres-Yaghi Y, Pagan FL, Liu X, Ressom H, Ahn J, Wolf C, Moussa C. Fowler AJ, et al. Among authors: liu x. Hum Mol Genet. 2020 Oct 10;29(17):2882-2898. doi: 10.1093/hmg/ddaa177. Hum Mol Genet. 2020. PMID: 32776088 Free PMC article.
Erratum to: Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.
Fowler AJ, Hebron M, Balaraman K, Shi W, Missner AA, Greenzaid JD, Chiu TL, Ullman C, Weatherdon E, Duka V, Torres-Yaghi Y, Pagan FL, Liu X, Ressom H, Ahn J, Wolf C, Moussa C. Fowler AJ, et al. Among authors: liu x. Hum Mol Genet. 2021 Jun 17;30(13):1271-1272. doi: 10.1093/hmg/ddab082. Hum Mol Genet. 2021. PMID: 34028526 Free PMC article. No abstract available.
125,476 results
You have reached the last available page of results. Please see the User Guide for more information.